Immunological basis in the pathogenesis and treatment of bladder cancer

Expert Review of Clinical Immunology

Volumn 11, Issue 2, 2015, Pages 265-279

  Thompson, David B ^a   Siref, Larry E ^a   Feloney, Michael P ^a   Hauke, Ralph J ^a   Agrawal, Devendra K ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BCG; bladder cancer; dendritic cells; macrophages; neutrophils; T cells; tumor vaccines; urothelial cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; ALPHA DEFENSIN; CANCER VACCINE; IL6 PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; BCG VACCINATION; BLADDER CANCER; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MACROPHAGE; NEUTROPHIL; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; URINARY TRACT INFECTION; GENETICS; IMMUNOLOGY; LEUKOCYTE; MYCOBACTERIUM BOVIS; PATHOLOGY; URINARY BLADDER NEOPLASMS;

ALPHA-DEFENSINS; CANCER VACCINES; HUMANS; INTERLEUKIN-6; LEUKOCYTES; MYCOBACTERIUM BOVIS; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 84921340375     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.983082     Document Type: Review

References (106)

1. Simons MP, Nauseef WM, Griffith TS. Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer. Immunol Res 2007; 39: 79-93
2. American Cancer Society. Cancer facts & figures 2014. Atlanta: American Cancer Society; 2014. Available from: www.cancer. org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf [Last accessed 7 June 2014]
3. Rossi R, Lichtner M, Iori F, et al. Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy. Arch Ital Urol Androl 2013; 85(4): 157-63
4. Van der Horst G, Bos L, van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol cancer Res 2012; 10(8): 995-1009
5. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003; 63: 8108-12
6. Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 2009; 106(33): 14016-21
7. Kompier LC, Lurkin I, van der Aa MNM, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010; 5(11): e13821
8. Apolo AB, Milowsky M, Bajorin DF. Clincial states model for biomarkers in bladder cancer. Future Oncol 2009; 5(7): 977-92
9. Shariat SF, Karam Ja, Lotan Y, et al. Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol 2008; 10(2): 120-35
10. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998; 160(3 Pt 1): 645-59
11. Chaffer CL, Brennan JP, Slavin JL, et al. Mesenchymal-To-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006; 66(23): 11271-8
12. Enkelmann A, Heinzelmann J, von Eggeling F, et al. Specific protein and miRNA patterns characterise tumour-Associated fibroblasts in bladder cancer. J Cancer Res Clin Oncol 2011; 137(5): 751-9
13. Tachibana M, Miyakawa A, Tazaki H, et al. Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor autocrine growth of transitional cell carcinoma of the bladder induced by. Cancer Res 1995; 55: 3438-43
14. Nieto MA, Cano A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Semin Cancer Biol 2012; 22: 361-8
15. Michaud DS. Chronic inflammation and bladder cancer. Urol Oncol 2007; 25(3): 260-8
16. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-Associated cancer. Nature 2004; 431(7007): 461-6
17. Stonehill W, Dmochowski R, Patterson A, et al. Risk factors for bladder tumors in spinal cord injury patients. J Urol 1996; 155: 1248-50
18. Locke JR, Hill DE, Walzer Y. Incidence of squamous cell carcinoma in patients with long-Term catheter drainage. J Urol 1985; 133(6): 1034-5
19. Marsh HP, Haldar NA, Bunce M, et al. Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer 2003; 89(6): 1096-101
20. Welk B, McIntyre A, Teasell R, et al. Bladder cancer in individuals with spinal cord injuries. Spinal Cord 2013; 51(7): 516-21
21. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140(6): 883-99
22. Tricker AR, Stickler DJ, Chawla JC, et al. Increased urinary nitrosamine excretion in paraplegic patients. Carcinogenesis 1991; 12(5): 943-6
23. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374: 239-49
24. Castelao JE, Yuan JM, Gago-Dominguez M, et al. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 2000; 82(7): 1364-9
25. Klan R, Knispel HH, Meier T. Acetylsalicylic acid inhibition of n-butyl-(4-hydroxybutyl) nitrosamine-induced bladder carcinogenesis in rats. J Cancer Res Clin Oncol 1993; 119(8): 482-5
26. Spencer JD, Schwaderer AL, Becknell B, et al. The innate immune response during urinary tract infection and pyelonephritis. Pediatr Nephrol 2014; 29(7): 1139-49
27. Beetz R. May we go on with antibacterial prophylaxis for urinary tract infections? Pediatr Nephrol 2006; 21(1): 5-13
28. Rahman H, Deka M. Detection & characterization of necrotoxin producing Escherichia coli (NTEC) from patients with urinary tract infection (UTI). Indian J Med Res 2014; 139(4): 632-7
29. Underwood MA, Bevins CL. Defensin-barbed innate immunity: clinical associations in the pediatric population. Pediatrics 2010; 125(6): 1237-47
30. Song J, Abraham SN. Innate and adaptive immune responses in the urinary tract. Eur J Clin Invest 2008; 38(Suppl 2): 21-8
31. Loughman JA, Hunstad DA. Attenuation of human neutrophil migration and function by uropathogenic bacteria. Microbes Infect 2011; 13(6): 555-65
32. Tittel AP, Heuser C, Ohliger C, et al. Kidney dendritic cells induce innate immunity against bacterial pyelonephritis. J Am Soc Nephrol 2011; 22(8): 1435-41
33. Thumbikat P, Waltenbaugh C, Schaeffer A, et al. Antigen-specific responses accelerate bacterial clearance in the bladder. J Immunol 2006; 176(5): 3080-6
34. Duell BL, Carey AJ, Tan CK, et al. Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection. J Immunol 2012; 188(2): 781-92
35. Khan MA, Travis LB, Lynch CF, et al. p53 mutations in cyclophosphamide-Associated bladder cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 397-403
36. Zhu Z, Shen Z, Xu C. Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm 2012; 2012: 1-11
37. Bronte V, Gabrilovich D. Myeloid-derived suppressor cells. Nat Rev Immunol 2010
38. Eruslanov E, Neuberger M, Daurkin I, et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J cancer 2012; 130(5): 1109-19
39. Robinson BD, Sica GL, Liu Y-F, et al. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 2009; 15(7): 2433-41
40. Sica A, Larghi P, Mancino A, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18(5): 349-55
41. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69(4): 1553-60
42. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166(1): 678-89
43. Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003; 6(4): 283-7
44. Suttmann H, Riemensberger J, Bentien G, et al. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 2006; 66(16): 8250-7
45. Gunes M, Gecit I, Pirincci N, et al. Plasma human neutrophil proteins-1,-2, and-3 levels in patients with bladder cancer. J Cancer Res Clin Oncol 2013; 139(2): 195-9
46. Albrethsen J, Bøgebo R, Gammeltoft S, et al. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 2005; 5: 8
47. Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001; 158(4): 1491-502
48. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek List 2001; 102(1): 5-14
49. Gondo T, Nakashima J, Ohno Y, et al. Prognostic value of neutrophil-To-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology 2012; 79(5): 1085-91
50. Hanada T, Nakagawa M, Emoto A, et al. Prognostic value of tumor-Associated macrophage count in human bladder cancer. Int J Urol 2000; 7(7): 263-9
51. Mantovani A, Locati M. Tumor-Associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscler Thromb Vasc Biol 2013; 33(7): 1478-83
52. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-Associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23(11): 549-55
53. Lima L, Oliveira D, Tavares A, et al. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure. Urol Oncol 2014; 32: 449-57
54. Ajili F, Kourda N, Darouiche A, et al. Prognostic value of tumor-Associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy. Ultrastruct Pathol 2013; 37(1): 56-61
55. Granata F, Frattini A, Loffredo S, et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol 2010; 184(9): 5232-41
56. Murdoch C, Lewis CE. Macrophage migration and gene expression in response to tumor hypoxia. Int J Cancer 2005; 117(5): 701-8
57. Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141(1): 39-51
58. Hofner T, Macher-Goeppinger S, Klein C, et al. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Urol Oncol 2014; 32(5): 678-86
59. Chen M-F, Lin P-Y, Wu C-F, et al. IL-6 expression regulates tumorigenicity and correlates with prognosis in bladder cancer. PLoS One 2013; 8(4): e61901
60. McConkey DJ, Choi W, Marquis L, et al. Role of epithelial-To-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009; 28: 335-44
61. Fondrevelle ME, Kantelip B, Reiter RE, et al. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol 2009; 27(3): 268-76
62. Ho PL, Lay EJ, Jian W, et al. Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Res 2012; 72(13): 3135-42
63. Wu M-L, Li H, Yu L-J, et al. Short-Term Exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One 2014; 9(2): e89806
64. Lee SJ, Park SS, Cho YH, et al. Activation of matrix metalloproteinase-9 by TNF-Alpha in human urinary bladder cancer HT1376 cells: the role of MAP kinase signaling pathways. Oncol Rep 2008; 19(4): 1007-13
65. Nishiyama T, Tachibana M, Horiguchi Y, et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific. Clin Cancer Res 2001; 7: 23-31
66. Beatty JD, Islam S, North ME, et al. Urine dendritic cells: a noninvasive probe for immune activity in bladder cancer? BJU Int 2004; 94(9): 1377-83
67. Shintani Y, Sawada Y, Inagaki T, et al. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy. Int J Urol 2007; 14(2): 140-6
68. Abadie V, Badell E, Douillard P, et al. Neutrophils rapidly migrate via lymphatics after Mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood 2005; 106(5): 1843-50
69. Ayari C, LaRue H, Hovington H, et al. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol 2009; 55: 1386-95
70. Ayari C, LaRue H, Hovington H, et al. High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer. Hum Pathol 2013; 44(8): 1630-7
71. Feyisetan O, Tracey C, Hellawell GO. Probiotics, dendritic cells and bladder cancer. BJU Int 2012; 109(11): 1594-7
72. Chen T, Wang H, Zhang Z, et al. A novel cellular senescence gene, SENEX, is involved in peripheral regulatory T cells accumulation in aged urinary bladder cancer. PLoS One 2014; 9(2): e87774
73. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127(4): 759-67
74. Furukawa J, Hara I, Nagai H, et al. Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. J Urol 2006; 176(3): 1198-203
75. Satyam A, Singh P, Badjatia N, et al. A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder. Urol Oncol 2011; 29(1): 58-65
76. Reijke TM, Boer EC, Kurth KH, et al. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996; 155(2): 477-82
77. Perabo FG, Kamp S, Schmidt D, et al. Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br J Cancer 2001; 84(10): 1330-8
78. Gruss HJ. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res 1996; 26(3): 143-59
79. Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272(51): 32401-10
80. Mizutani Y, Yoshida O, Miki T. Adriamycin-mediated potentiation of cytotoxicity against freshly isolated bladder cancer cells by autologous non-Activated peripheral blood lymphocytes and tumor infiltrating lymphocytes. J Urol 1999; 162(6): 2170-5
81. American Cancer Society. American Cancer Society: bladder cancer. 2014. Available from: www.cancer.org/acs/groups/cid/documents/webcontent/003085-pdf.pdf [Last accessed 22 July 2014]
82. Gándara L, Sandes E, Di Venosa G, et al. The natural flavonoid silybin improves the response to photodynamic therapy of bladder cancer cells. J Photochem Photobiol B 2014; 133: 55-64
83. Richterstetter M, Wullich B, Amann K, et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int 2012; 110: 76-9
84. Highley MS, van Oosterom AT, Maes RA, et al. Intravesical drug delivery. Pharmacokinetic and clinical considerations. Clin Pharmacokinet 1999; 37(1): 59-73
85. Bazarbashi S, Soudy H, Abdelsalam M, et al. Co-Administration of intravesical bacillus Calmette-Guérin and interferon a-2B as first line in treating superficial transitional cell carcinoma of the urinary bladder. BJU Int 2011; 108(7): 1115-18
86. Maffezzini M, Campodonico F, Canepa G, et al. Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression. Cancer Chemother Pharmacol 2014; 73(5): 925-30
87. Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase. Lancet Oncol 2013; 14(9): 863-72
88. Koie T, Ohyama C, Hashimoto Y, et al. Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-Arm study. Int J Clin Oncol 2013; 18(4): 724-30
89. Aluwini S, van Rooij PHE, Kirkels WJ, et al. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: long-Term results. Int J Radiat Oncol Biol Phys 2014; 88(3): 611-17
90. Luo Y, Knudson MJ. Mycobacterium bovis bacillus Calmette-Guerin-induced macrophage cytotoxicity against bladder cancer cells. Clin Dev Immunol 2010; 2010: 357591
91. Jackson AM, Alexandroff AB, Kelly RW, et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-l) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 1995; 99: 369-75
92. Brincks EL, Risk MC, Griffith TS. PMN and anti-Tumor immunity-The case of bladder cancer immunotherapy. Semin Cancer Biol 2013; 23(3): 183-9
93. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003; 170: 964-9
94. Jinesh GG, Chunduru S, Kamat AM. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-A but not through TRAIL and FasL. J Leukoc Biol 2012; 92(1): 233-44
95. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3(6): 673-82
96. Simons MP, ÓDonnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol 2008; 26(4): 341-5
97. Takayama H, Nishimura K, Tsujimura A, et al. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol 2009; 181(4): 1894-900
98. Luo Y, Blocking IL-10 enhances bacillus Calmette-Guérin induced T helper Type 1 immune responses and anti-bladder cancer immunity. Oncoimmunology 2012; 1(7): 1183-5
99. Bohle A, Gerdes J, Ulmer A, et al. Effects of local Bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144: 53-8
100. Takeuchi A, Dejima T, Yamada H, et al. IL-17 production by gd T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guerin treatment against bladder cancer. Eur J Immunol 2011; 41: 246-51
101. Shiozaki EN, Shi Y. Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 2004; 29(9): 486-94
102. Saito S, Bannerji R, Gansbacher B, et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 1994; 54: 3516-20
103. Bubenik J. Cytokine vaccines in the therapy of cancer. Pharmacol Ther 1996; 69(1): 1-14
104. Raghavan D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer. N Engl J Med 1990; 322(16): 1129-38
105. Soloway MS, Murphy WM. Experimental chemotherapy of bladder cancer-systemic and intravesical. Semin Oncol 1979; 6(2): 166-83
106. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-Tumor immunity. Proc Natl Acad Sci USA 1993; 90(8): 3539-43